𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Collagen α1(XI) in normal and malignant breast tissue

✍ Scribed by Halsted, Karen C; Bowen, Kara B; Bond, Laura; Luman, Sarah E; Jorcyk, Cheryl L; Fyffe, William E; Kronz, Joseph D; Oxford, Julia T


Book ID
109887554
Publisher
Nature Publishing Group
Year
2008
Tongue
English
Weight
399 KB
Volume
21
Category
Article
ISSN
0893-3952

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Midkine and pleiotrophin expression in n
✍ Robert I. Garver Jr.; Diane M. Radford; Helen Donis-Keller; Mark R. Wick; Peter 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 805 KB

Background. Some growth factors may promote tumor growth by affecting tumor angiogenesis. The angiogenic growth factor, pleiotrophin, was demonstrated previously in human breast carcinoma tissues; however, the pattern of pleiotrophin expression in normal breast tissues has not been established. Met

Study of FHIT transcripts in normal and
✍ Ivan Bièche; Alain Latil; Véronique Becette; Rosette Lidereau 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB 👁 2 views

Cytogenetic and molecular studies have suggested that the 3p14.2 chromosome subband contains tumor suppressor genes involved in the pathogenesis of many types of human cancers. Recently, the FHIT (fragile histidine triad) gene was identified in this part of chromosome 3 as a candidate suppressor gen

Factor X-activating procoagulant in norm
✍ Khaled El-Baruni; Irving Taylor; Stuart Roath; Dr. John L. Francis 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 602 KB

## Abstract Factor X‐activating activity (FXAA) was determined by a chromogenic assay in normal and malignant breast tissue. FXAA was found in all tissue (__n__ = 38) irrespective of pathology, and the activity of normal tissue was similar to that of tumours. FXAA correlated with tissue hemoglobin

Concentrations of oestrone and 4-hydroxy
✍ M. J. Reed; G. W. Aherne; M. W. Ghilchik; S. Patel; J. Chakraborty 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 477 KB

## Abstract 4‐Hydroxyandrostenedione (4‐OHA) is a specific inhibitor of aromatase activity used for the treatment of breast cancer in post‐menopausal women. Treatment with 4‐OHA has been shown to inhibit the peripheral conversion of androstenedione to oestrone and reduce plasma oestrogen concentrat